Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Metastatic Gastric Cancer Histology confirmed adenocarcinoma of stomach. 2. Stage IV (AJCC 7.0) 3. Malnourished patients with nutritional risk index (NRI) < 97.5. NRI= 1.59 x serum albumin level (g/L) + 0.417 x (current weight/usual weight) x 100 4. Adequate organ function as defined by the following absolute neutrophil count (ANC) > or =1500 cells/mm3 platelets > or =60,000 cells/mm3 hemoglobin > or =8.0 g/dL AST and ALT < or =3.0 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT< or =5.0 x ULN total bilirubin < or =2.0x ULN serum creatinine < or =2.0 x ULN or calculated creatinine clearance > or =60 mL/min 5. Male or female, age > or = 20 years and < 80 years. 6. Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment. 7. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment  Known allergy to components of studied parenteral nutrition. 2. Acute shock or collapse. 3. Known diabetic ketoacidosis 7 days prior to randomization. 4. Unstable conditions (e.g. uncompensated diabetes mellitus, acute myocardial infarction, embolism, metabolic acidosis, severe sepsis and hypotonic dehydration). 5. General contraindications to infusion therapy: acute pulmonary edema, hyperhydration, uncompensated cardiac insufficiency. 6. Investigator judges as subjects to be inappropriate for the clinical study (e.g., patient with severe complications) 7. Active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis. 8. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness. 9. Participation in another clinical study with an investigational drug or an investigational medical device within 1 month prior to start of the study or during the study. 10. Female patients who are pregnant or lactating, or men and women of reproductive potential not willing or not able to employ an effective method of birth control/contraception to prevent pregnancy during treatment and for 6 months after discontinuing study treatment. The definition of effective contraception should be in agreement with local regulation and based on the judgment of the principal investigator or a designated associate